WallStSmart
AZN

AstraZeneca PLC

NYSE: AZN · HEALTHCARE · DRUG MANUFACTURERS - GENERAL

$177.89
-0.46% today

Updated 2026-06-17

Market cap
$282.69B
P/E ratio
27.49
P/S ratio
4.68x
EPS (TTM)
$6.63
Dividend yield
1.79%
52W range
$135 – $211
Volume
2.0M

WallStSmart proprietary scores

64
out of 100
Grade: C+
Hold
Investment rating
6.0
Growth
B
5.0
Quality
C+
8.5
Profitability
A
6.0
Valuation
B
6/9
Piotroski F-Score
Moderate
1.5
Altman Z-Score
Distress
Industry rank
View all highly rated stocks (75+) →199 stocks currently score above 75

Price targets

Analyst target
$224.49
+26.20%
12-Month target
$233.94
+31.51%
Intrinsic (DCF)
$194.77
Margin of safety
+8.23%
2 Strong Buy7 Buy1 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths
+ ROE 21.95% — strong efficiency
+ Free cash flow $1.82B — positive
+ Revenue growth 12.50% QoQ
Risks
- Altman Z 1.48 — distress zone

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM2026 (E)
Revenue$44.35B$45.81B$54.07B$58.74B$60.44B$72.8B
Net income$3.29B$5.96B$7.04B$10.26B$3.08B
EPS$6.63$6.10
Free cash flow$7.24B$6.57B$7.28B$11.77B$1.82B
Profit margin7.41%13.00%13.01%17.46%17.20%

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
AZN$282.69B646.08.56.05.0+8.23%Buy
LLY$1.01T7610.010.04.36.0Strong Buy
JNJ$567.28B574.79.03.36.0-73.18%Buy
ABBV$391.50B634.08.04.05.0-52.38%Buy
UNH$373.28B545.35.54.05.5-26.94%Buy
NVS$289.19B493.39.03.34.5-65.15%Hold

Smart narrative

AstraZeneca PLC trades at $177.89. representing a P/E of 27.49x trailing earnings. Our Smart Value Score of 64/100 indicates the stock is good. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 1.48, it sits in the distress. TTM revenue stands at $60.44B. with profit margins at 17.20%. Our DCF model estimates intrinsic value at $194.77.

Frequently asked questions

What is AstraZeneca PLC's stock price?

AstraZeneca PLC (AZN) trades at $177.89, on a P/E of 27.5x and a P/S of 4.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.

Is AstraZeneca PLC overvalued?

AstraZeneca PLC carries a Smart Value Score of 64/100 (Grade C+), which we rate Hold. That score blends growth, quality, and valuation into one read. Our DCF puts intrinsic value at $194.77 versus the $177.89 price, a 8.2% margin of safety on a cash flow basis.

What is the price target of AstraZeneca PLC (AZN)?

The 12-month analyst consensus target is $224.49, about 26.2% above the current $177.89. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

What is the future stock price of AZN by 2030?

Our research-backed model puts the 2030 base case at $164.40, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.

What is the intrinsic value of AstraZeneca PLC (AZN)?

Our DCF model estimates intrinsic value at $194.77, a +8.2% margin of safety versus today's $177.89. Intrinsic value is what the projected cash flows are worth today. A positive reading means the price sits below that estimate, leaving a cushion if growth holds.

What is AstraZeneca PLC's revenue?

AstraZeneca PLC's trailing twelve-month revenue is $60.44B, and our model projects it reaching about $127.80B by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.

Altman Z-Score?

AstraZeneca PLC's Altman Z-Score is 1.48, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - GENERAL
CountryUSA
ExchangeNYSE
CurrencyUSD

Quick metrics

P/S ratio4.68x
ROE21.95%
Beta0.21
50D MA$189.58
200D MA$181.96
Shares out1.55B
Float1.54B
Short ratio
Avg volume2.0M

Performance

1 week+0.00%
1 month+0.71%
3 months-1.58%
YTD+102.27%
1 year
3 years
5 years